**No hantavirus vaccine is expected to reach licensure or broad availability in 2026.** Most candidates remain in preclinical or early Phase 1 stages, with promising mRNA and DNA platforms showing strong immunogenicity and protection in animal models (e.g., single-dose mRNA constructs from UTMB and Korea University/Moderna collaborations). However, no large-scale Phase 3 efficacy trials are underway, and standard regulatory pathways for safety, manufacturing, and human testing typically span multiple years even with accelerated funding. Recent outbreaks have heightened visibility but have not yet triggered emergency-use pathways or shifted candidates into late-stage development. Market-implied odds align with these timelines, though a major outbreak or unexpected fast-track authorization could alter trajectories before year-end.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhậtHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% khả năng
$130,685 KL.
$130,685 KL.
Dec 30, 2026
6% khả năng
$130,685 KL.
$130,685 KL.
Dec 30, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**No hantavirus vaccine is expected to reach licensure or broad availability in 2026.** Most candidates remain in preclinical or early Phase 1 stages, with promising mRNA and DNA platforms showing strong immunogenicity and protection in animal models (e.g., single-dose mRNA constructs from UTMB and Korea University/Moderna collaborations). However, no large-scale Phase 3 efficacy trials are underway, and standard regulatory pathways for safety, manufacturing, and human testing typically span multiple years even with accelerated funding. Recent outbreaks have heightened visibility but have not yet triggered emergency-use pathways or shifted candidates into late-stage development. Market-implied odds align with these timelines, though a major outbreak or unexpected fast-track authorization could alter trajectories before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Thị trường mở: May 4, 2026, 10:39 AM ET
Khối lượng
$130,685Ngày kết thúc
Dec 31, 2026Thị trường mở
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**No hantavirus vaccine is expected to reach licensure or broad availability in 2026.** Most candidates remain in preclinical or early Phase 1 stages, with promising mRNA and DNA platforms showing strong immunogenicity and protection in animal models (e.g., single-dose mRNA constructs from UTMB and Korea University/Moderna collaborations). However, no large-scale Phase 3 efficacy trials are underway, and standard regulatory pathways for safety, manufacturing, and human testing typically span multiple years even with accelerated funding. Recent outbreaks have heightened visibility but have not yet triggered emergency-use pathways or shifted candidates into late-stage development. Market-implied odds align with these timelines, though a major outbreak or unexpected fast-track authorization could alter trajectories before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Khối lượng
$130,685Ngày kết thúc
Dec 31, 2026Thị trường mở
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...**No hantavirus vaccine is expected to reach licensure or broad availability in 2026.** Most candidates remain in preclinical or early Phase 1 stages, with promising mRNA and DNA platforms showing strong immunogenicity and protection in animal models (e.g., single-dose mRNA constructs from UTMB and Korea University/Moderna collaborations). However, no large-scale Phase 3 efficacy trials are underway, and standard regulatory pathways for safety, manufacturing, and human testing typically span multiple years even with accelerated funding. Recent outbreaks have heightened visibility but have not yet triggered emergency-use pathways or shifted candidates into late-stage development. Market-implied odds align with these timelines, though a major outbreak or unexpected fast-track authorization could alter trajectories before year-end.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật
Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp